EDI19E9 is an immunogenicity-reduced antibody against the human erythrocyte complement receptor 1 (CR1). EDI19E9 comprises several amino acid substitutions so that the immunogenicity-reduced antibody is non-immunogenic or less immunogenic to a human.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-240 | Recombinant Anti-human CR1 Antibody | ELISA, WB, IF, FuncS | IgG |
MOB-0284MZ | Recombinant Mouse Anti-Human Complement Component (3b/4b) Receptor 1 (Knops blood group) Antibody (clone Cer-MAC-DRC1) | IHC | Mouse antibody |
HPAB-J0316-YC | Human Anti-CR1 Recombinant Antibody (HPAB-J0316-YC) | ELISA | Human HC IgG2 |
HPAB-J0317-YC | Human Anti-CR1 Recombinant Antibody (HPAB-J0317-YC) | ELISA | Human HC IgG3 |
HPAB-J0318-YC | Human Anti-CR1 Recombinant Antibody (HPAB-J0318-YC) | ELISA | Human HC IgG2 |
There are currently no Customer reviews or questions for HPAB-0423-CN-S(P). Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.